Servier announced today in a community letter that the company is stopping its clinical development program for sevasemten, including studies in both Duchenne and Becker muscular dystrophy.
This news is deeply disappointing for the Duchenne and Becker communities. It comes just days after Servier announced that the pivotal Phase 3 GRAND CANYON study of sevasemten in Becker did not meet its primary or secondary endpoints. Now, the termination of the broader development program represents another significant setback for individuals and families who had been following this research and hoping it might lead to a new therapeutic option.
What does this mean?
Sevasemten, formerly known as EDG-5506, is an orally administered small molecule inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. Sevasemten’s development originated with Edgewise Therapeutics, which was acquired by Servier in 2026.
The recent GRAND CANYON results in Becker showed that sevasemten did not provide benefit on the primary—North Star Ambulatory Assessment (NSAA)—or key secondary functional endpoints. Following review of the GRAND CANYON, LYNX, and FOX study data, Servier indicated that a Governance Committee determined that there was insufficient evidence to support continued development of sevasemten in either Becker or Duchenne. The company noted that it will conduct in-depth analyses of the data to better understand the results and share their learnings with the community.
PPMD will be hosting a community webinar with Servier on Tuesday, November 17, 2026, at 1:00 PM ET to discuss updates from the topline date of the GRAND CANYON study for Becker muscular dystrophy and implications for future Becker and Duchenne trials. Register for the webinar here and submit questions in advance here.
What comes next
We recognize how difficult and discouraging this news is for many in our community, particularly for individuals and families who participated in these studies, supported loved ones through the clinical trial process, or have been following the development of sevasemten with optimism for a potential therapeutic option. Every clinical trial requires an extraordinary commitment from participants, families, caregivers, investigators, and research teams, and we are deeply grateful to everyone who contributed to this research. Your time, trust, and willingness to participate in clinical studies matter, even when the outcomes are not what we had hoped.
We also acknowledge and are grateful for the tremendous work Edgewise did to build, foster, and support the Duchenne and Becker community throughout the development of sevasemten.
Another stopped investigational treatment program can leave families feeling frustrated, uncertain, and wondering what comes next. There is still important work happening across Duchenne and Becker research. PPMD will continue to push for investment in research, support the development of promising therapeutic approaches, advocate for meaningful clinical trial opportunities, and ensure that the experiences and priorities of individuals and families remain central to the work ahead.
Individuals currently participating in a sevasemten clinical trial or who have participated in a study should contact their clinical trial site or study team directly for information about the termination, study follow-up, and any next steps related to their participation. Questions about individual care and treatment should be directed to a healthcare provider.
PPMD will continue working to obtain additional information from Servier and will keep the community informed as we learn more. We are here for individuals and families across every stage and every journey, and we will continue this work together.
Read Servier’s community letter here.
The post Servier Stops Clinical Development of Sevasemten in Duchenne and Becker Muscular Dystrophy appeared first on Parent Project Muscular Dystrophy.